Skip to main content
. 2016 Jul 26;3(4):293–298. doi: 10.1002/ehf2.12101

Figure 1.

Figure 1

(a) Temporal changes in median of cardiac magnetic resonance T2* sequence after intravenous ferric carboximaltose administration. (b) ΔLVEF and ΔT2*, adjusting for anaemia at baseline. (C) ΔLVEF and ΔT2* adjusting for changes in haemoglobin. CMR, cardiac magnetic resonance; FCM, ferric carboximaltose; ΔLVEF, changes in left ventricular ejection fraction; ΔT2*, changes in T2*.